INTRODUCTION
Gram-negative bacterial infections cause intractable shock and death with disturbingly high frequency despite antibiotic treatment. This failure of antimicrobial agents has been blamed partly on bacterial lipopolysaccharides from dead organisms. For this reason, we are investigating antiserum against endotoxin for treatment of these infections.
Although it had been recognized for many years that serum from patients recovering from typhoid fever could protect guinea pigs from lethal challenge with live or-ganisms (1), Abernathy and Spink, using a Brucella model, were first to show that human convalescent serum could neutralize endotoxin (2) . This observation, supported by extensive evidence that passive immunization with rabbit antiserum can protect against mouse lethality from endotoxin and the local and generalized Shwartzman reactions (3) (4) (5) (6) , has led us to study the ability of serum from immunized human subjects to protect against endotoxin. The chi-square test was used to determine if the incidence of Shwartzmain reactions in antiserum-treated groups was significantly less than in the controls.
METHODS

RESULTS
Production of antiserum. The subjects who received S. typhimurium vaccine responded with a 3-to 11-fold rise (average 6-fold) in hemagglutinating antibody titer to homologous endotoxin. Final titers ranged from 1: 512 to 1: 8,000 (geometric mean 1: 1,550). Men who were given E. coli cells had a 6-to 10-fold titer rise 'Rancho de Conejo, Vista, Calif.
(average 8-fold), with final titers of from 1: 4,000 to 1: 16,000 (geometric mean 1: 4,700). Peak responses in both groups occurred from 6 to 14 days and averaged 10 days. Both vaccines elicited mild local erythema, induration, and moderate tenderness with no disability. Occasional mild febrile reactions were controlled with aspirin.
Protection against maouse lethality. 1 ml of human antiserum i.v. gave excellent protection against death from homologous endotoxin, exceeding the 0.5% level of significance in all cases (Table I ). With 0.5 ml antiserum i.v. protection was no longer evident. However, 0.5 ml of S. typhinturium antiserum given i.p. produced a small but significant .reduction in mortality. Attempts to demonstrate heterologous protection by using E. coli antiserum against S. typhimurium endotoxin and vice versa, were not successful. Anaphylactic deaths occurred only with S. typhimurium antiserum and homologous endotoxin; there were 5/32 deaths at 1 h with 1.0 ml and 1/32 with 0.5 ml antiserum.
Prevention of the local Shwartzman reaction. Antiserum from subjects immunized with S. typhimurium strikingly reduced the frequency of Shwartzman reactions (Table II) with S. typhimurium endotoxin from 92 to 35%. Antiserum from those immunized with E. coli 0: 111 endotoxin lowered the frequency of Shwartzman reactions with E. coli 0: 111 from 100 to 38% (P < 0.0005 for both sets of experiments). Protection correlated to some extent with both titer and volume of antiserum. We occasionally encountered preprovocativepositive reactions with S. typhimturium endotoxin and discarded those animals from the series. S. typhimurium antiserum provided no heterologous protection against E. coli endotoxin. The immunization schedule is simple, side effects are minimal, and "O" antibody response compares favorably with that achieved after two injections of typhoid vaccine a month apart (11, 12) . Immunoglobulin fractionation studies were not performed because it has been shown that both 7S and 19S fractions contain protective "O" antibody (6 In contrast to the excellent protection against homologous endotoxins, these human antisera against smooth organisms were of no value in preventing the Shwartzman reaction or death from heterologous endotoxins. This failure of heterologous protection with smooth antisera has been reported earlier against both endotoxins and viable bacteria and can be explained by the concept that "O" determinants conceal the common core of endotoxin. Using antiserum from animals immunized with "O"-deficient mutants whose "core" is unencumbered by "O" side chains, We have shown excellent heterologous protection against death from endotoxin (4), the local Shwartzman reaction (5), disseminated intravascular coagulation (6) , and lethal bacteremia (13) . Chedid, Parant, Parant, and Boyer (14) and McCabe (15) have obtained similar protection against mouse bacteremia. Encouraged by these results we are now immunizing human subjects with "O"-deficient mutant vaccines.
